Weight maintenance on cost‐effective antiobesity medications after 1 year of GLP‐1 receptor agonist therapy: a real‐world study
Authors' conclusion
Patients successfully treated with GLP-1 RAs can maintain their weight loss using generic older-generation AOMs, suggesting potential cost savings for insurers and implications for policy regarding AOM coverage.
Study context
- Population
- Patients who completed 12 months of GLP-1 RA therapy in a medical weight loss bundle (12 months GLP-1 RA then 6 months transition care) with successful weight loss; baseline mean BMI 36.4 kg/m²40 transitioned to antiobesity medications (AOMs)
- Participants
- 105 patients
- Exposure
- Generic older-generation AOMs for weight maintenance after 12 months of GLP-1 RA therapy
- Generic AOMsn = 40
- Outcome
- Body weight outcomes
- Follow-up
- 6, 12, 18 and 24 months
Methodological detailssingle-group
- Single-group
Main finding
As reported in the abstract
12 and 18 months
Average body weight loss from baseline at 12 months
18.3%, 95% CI 13.0%–23.6%
Mean BMI at 12 months
27.9 kg/m²
Weight loss maintained at 18 months; mean BMI
27.9 kg/m²
Observational data: associations, not effects.
Further findings
Total weight loss vs initial visit at subsequent follow-up without GLP-1 RAs · average 1.5 months after 18 months
- Total average weight loss vs initial visit
- 25.5%, 95% CI 23.1%–27.9%
Original publication
Weight maintenance on cost‐effective antiobesity medications after 1 year of GLP‐1 receptor agonist therapy: a real‐world study. Obesity (Silver Spring). Published 18 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →